- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.04. | Sixty Degrees Pharmaceuticals: 60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis | 1 | GlobeNewswire (USA) | ||
| 01.04. | 60 DEGREES PHARMACEUTICALS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 14.03. | FDA to review 60 Degrees Pharmaceuticals trial in April | 1 | Investing.com | ||
| 28.02. | 60 DEGREES PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.02. | 60 DEGREES PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.01. | Sixty Degrees Pharmaceuticals: 60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 30.01. | 60 Degrees Pharmaceuticals stock sinks on pricing of $2.4M public offering | 1 | Seeking Alpha | ||
| 30.01. | Sixty Degrees Pharmaceuticals: 60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 30.01. | Why Is 60 Degrees (SXTP) Stock Down 33% Today? | 3 | InvestorPlace | ||
| 22.01. | 60 Degrees Pharmaceuticals files to sell 4.79M units | 2 | Seeking Alpha | ||
| 22.01. | 60 DEGREES PHARMACEUTICALS, INC. - S-1, General form for registration of securities | - | SEC Filings | ||
| 22.01. | 60 Degrees Pharmaceuticals Outlines Plans For Rare Tick-Borne Infection Trial Evaluating Its Malaria Drug | 1 | Benzinga.com | ||
| 16.01. | 60 DEGREES PHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 26.12.23 | Sixty Degrees Pharmaceuticals: 60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024 | 235 | GlobeNewswire (Europe) | Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma's double-blind, placebo-controlled study to investigate tafenoquine for treatment of hospitalized babesiosis patientsThe... ► Artikel lesen | |
| 20.11.23 | 60 DEGREES PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.11.23 | 60 DEGREES PHARMACEUTICALS, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 15.11.23 | 60 Degrees to meet with FDA over developing Arakoda for babesiosis | 1 | Seeking Alpha | ||
| 15.11.23 | Sixty Degrees Pharmaceuticals: 60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease | 2 | GlobeNewswire (USA) | ||
| 01.09.23 | Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report on Bloomberg TV | 549 | ACCESSWIRE | ORLANDO, FL / ACCESSWIRE / September 1, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (Nasdaq:GENE) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on The RedChip Money... ► Artikel lesen | |
| 14.07.23 | Sixty Degrees Pharmaceuticals: 60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering | 676 | GlobeNewswire (Europe) | WASHINGTON, July 14, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), specialists in developing and marketing medicines for infectious diseases... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 114,02 | -2,21 % | Novo Nordisk vor Zahlen: Das erwarten die Analysten | Europas wertvollstes börsennotiertes Unternehmen öffnet am Donnerstag in dieser Handelswoche (02. Mai) seine Bücher zum ersten Quartal. DER AKTIONÄR zeigt auf, was die Analysten im Durchschnitt vom... ► Artikel lesen | |
| TEVA | 13,050 | -0,76 % | Teva feiert 50 Jahre ratiopharm / Jubiläumsveranstaltung von Deutschlands bekanntester Arzneimittelmarke | Ulm (ots) - Gute Preise. Gute Besserung. Dieses Versprechen hält ratiopharm als erstes deutsches Generika Unternehmen seit 1973. 50 Jahre später, 2023, feierte Teva den runden ratiopharm-Geburtstag... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 369,85 | -0,82 % | Vertex Pharmaceuticals: Vertex Announces European Commission Approval for KALYDECO to Treat Infants With Cystic Fibrosis Ages 1 Month and Older | KALYDECO is the first and only medicine approved in the EU in this age group to treat the underlying cause of cystic fibrosis for specific mutations in the CFTR gene - Vertex Pharmaceuticals... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 9,380 | +0,32 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| APONTIS PHARMA | 8,260 | -0,24 % | Original-Research: Apontis Pharma AG (von Montega AG): Kaufen | Original-Research: Apontis Pharma AG - von Montega AG Einstufung von Montega AG zu Apontis Pharma AG Unternehmen: Apontis Pharma AG ISIN: DE000A3CMGM5 Anlass der Studie: Update Empfehlung:... ► Artikel lesen | |
| XORTX THERAPEUTICS | 2,440 | -3,17 % | XORTX ändert Preis von Warrants, die im Rahmen früherer Privatplatzierungen ausgegeben wurden | CALGARY, AB - 30. April 2024 / IRW-Press / XORTX Therapeutics Inc. ("XORTX" oder das "Unternehmen") (NASDAQ: XRTX | TSXV: XRTX | FWB: ANU), ein auf spätklinische Studien spezialisiertes... ► Artikel lesen | |
| TG THERAPEUTICS | 14,906 | -2,59 % | Pre-market Movers: IM Cannabis, CVRx, TG Therapeutics, Root, Inc., Plutonian Acquisition | WOONSOCKET (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 09.00 A.M. ET).In the Green IM Cannabis Corp. (IMCC) is up over 36% at $0.86.
TG... ► Artikel lesen | |
| CATALENT | 52,43 | -0,19 % | FTC seeks more information on Novo Holdings-Catalent deal | ||
| CORBUS PHARMACEUTICALS | 36,200 | +1,69 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update | Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1 study... ► Artikel lesen | |
| ROCKET LAB USA | 3,750 | +1,90 % | What's Going On With Rocket Lab Shares Today? | ||
| BOIRON | 34,000 | 0,00 % | BOIRON: Outlook 2023 - Communication calendar 2024 | The Board of Directors of Laboratoires BOIRON met on 19 December 2023, under the chairmanship of Mr Thierry Boiron.
At this meeting, the Board reviewed the latest business and earnings forecasts... ► Artikel lesen | |
| AVALO THERAPEUTICS | 15,350 | +5,14 % | Avalo Therapeutics Inc expected to post a loss of $1.18 a share - Earnings Preview | ||
| MEDICINOVA | 1,340 | +24,07 % | MediciNova, Inc.: MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) | LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| SOLID BIOSCIENCES | 10,230 | -0,10 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases... ► Artikel lesen | |
| ESSA PHARMA | 6,960 | +0,43 % | Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders | SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing... ► Artikel lesen |
60 DEGREES PHARMACEUTICALS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -7,84 % bei einem Aktienkurs von 0,214 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
